183 related articles for article (PubMed ID: 32259295)
1. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
[TBL] [Abstract][Full Text] [Related]
2. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
Ramaswamy A; Bhandare M; Bal M; Shrirangwar S; Kataria P; Majumdar S; Swami R; Rohila J; Chaudhari V; Mandavkar S; Chavan N; Shrikhande SV; Ostwal V
HPB (Oxford); 2020 Mar; 22(3):376-382. PubMed ID: 31405778
[TBL] [Abstract][Full Text] [Related]
5. Oncologic outcomes in resected ampullary cancer: Relevance of histologic subtype and adjuvant chemotherapy.
Affi Koprowski M; Sutton TL; Brinkerhoff BT; Grossberg A; Sheppard BC; Mayo SC
Am J Surg; 2021 Jun; 221(6):1128-1134. PubMed ID: 33883071
[TBL] [Abstract][Full Text] [Related]
6. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater.
Schiergens TS; Reu S; Neumann J; Renz BW; Niess H; Boeck S; Heinemann V; Bruns CJ; Jauch KW; Kleespies A
Surgery; 2015 Jul; 158(1):151-61. PubMed ID: 25819575
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.
Jiang ZQ; Varadhachary G; Wang X; Kopetz S; Lee JE; Wang H; Shroff R; Katz M; Wolff RA; Fleming J; Overman MJ
Ann Oncol; 2013 Sep; 24(9):2349-53. PubMed ID: 23704197
[TBL] [Abstract][Full Text] [Related]
9. Defining the role of adjuvant external beam radiotherapy on resected adenocarcinoma of the ampulla of vater.
Miura JT; Jayakrishnan TT; Amini A; Johnston FM; Tsai S; Erickson B; Quebbeman EJ; Christians KK; Evans DB; Gamblin TC; Turaga KK
J Gastrointest Surg; 2014 Nov; 18(11):2003-8. PubMed ID: 25159502
[TBL] [Abstract][Full Text] [Related]
10. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Showalter TN; Zhan T; Anne PR; Chervoneva I; Mitchell EP; Yeo CJ; Rosato EL; Kennedy EP; Berger AC
J Gastrointest Surg; 2011 Aug; 15(8):1411-6. PubMed ID: 21523621
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy using gemcitabine for resected distal bile duct and ampullary cancers.
Suzuki S; Kaji S; Koike N; Harada N; Suzuki M; Hayashi T
Hepatogastroenterology; 2014; 61(130):314-8. PubMed ID: 24901131
[TBL] [Abstract][Full Text] [Related]
12. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis.
Kamarajah SK
Clin Transl Oncol; 2018 Sep; 20(9):1212-1218. PubMed ID: 29497964
[TBL] [Abstract][Full Text] [Related]
14. 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas.
Onkendi EO; Boostrom SY; Sarr MG; Farnell MB; Nagorney DM; Donohue JH; Kendrick ML; Reid-Lombardo KM; Harmsen WS; Que FG
J Gastrointest Surg; 2012 Apr; 16(4):682-91. PubMed ID: 22350721
[TBL] [Abstract][Full Text] [Related]
15. Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
Kim HS; Shin SJ; Kim JH; Kim H; Choi HJ
Tohoku J Exp Med; 2013 Sep; 231(1):21-8. PubMed ID: 23994910
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study.
Bolm L; Ohrner K; Nappo G; Rückert F; Zimmermann C; Rau BM; Petrova E; Honselmann KC; Lapshyn H; Bausch D; Weitz J; Sandini M; Keck T; Zerbi A; Distler M; Wellner UF
Pancreatology; 2020 Apr; 20(3):433-441. PubMed ID: 31987649
[TBL] [Abstract][Full Text] [Related]
17. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis of pancreatic and periampullary collision cancers.
Niu GM; Jin DY; Ji Y; Hou J; Wang DS; Lou WH
J Dig Dis; 2010 Aug; 11(4):231-6. PubMed ID: 20649736
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Narang AK; Miller RC; Hsu CC; Bhatia S; Pawlik TM; Laheru D; Hruban RH; Zhou J; Winter JM; Haddock MG; Donohue JH; Schulick RD; Wolfgang CL; Cameron JL; Herman JM
Radiat Oncol; 2011 Sep; 6():126. PubMed ID: 21951377
[TBL] [Abstract][Full Text] [Related]
20. Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis.
Kamarajah SK; Bednar F; Cho CS; Nathan H
J Gastrointest Surg; 2021 Jul; 25(7):1805-1814. PubMed ID: 33230687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
